Physician profile
Alfred P Rosche
NPI 1962448332
$5,450.53
in general payments reported to CMS, 2019-2025
29 companies · $885 in 2025
The $885 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $170 · 2021: $356 · 2022: $133 · 2023: $336 · 2024: $3,216 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Travel and Lodging: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.00 |
| Travel and Lodging | $1,895.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,918.51 | 2024-2025 | Ha Minuteman G3-R, Liberty Si |
| Boston Scientific Corporation | $953.62 | 2019-2025 | Intracept Rf Probe, General - Pain Management, Intracept |
| Pfizer INC. | $701.74 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $464.20 | 2019-2025 | Nucynta, Belbuca |
| Stryker Corporation | $307.01 | 2022-2024 | Optablate, Spinejack |
| Amgen INC. | $177.03 | 2019-2022 | |
| Abbott Laboratories | $106.31 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kowa Pharmaceuticals America, INC. | $89.17 | 2019-2023 | Seglentis |
| Fidia Pharma USA INC. | $87.36 | 2024 | Hymovis, Triluron, Hyalgan |
| Bausch Health US, LLC | $70.35 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $64.98 | 2024-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $45.31 | 2023-2025 | Wegovy |
| Saluda Medical Americas, INC. | $41.64 | 2025 | Evoke |
| Exact Sciences Corporation | $41.49 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $39.10 | 2025 | Movantik |
| Ferring Pharmaceuticals INC. | $38.29 | 2025 | Euflexxa |
| Abbvie INC. | $25.62 | 2022-2023 | Botox |
| Alnylam Pharmaceuticals INC. | $25.39 | 2023 | Amvuttra |
| Avanos Medical | $18.56 | 2024 | Coolief* Cooled Radiofrequency |
| Relievant Medsystems, INC. | $18.30 | 2023 | Intracept |
| Biohaven Pharmaceutical Holding Company LTD. | $17.19 | 2022 | |
| Lilly USA, LLC | $16.57 | 2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $16.46 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.37 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $14.27 | 2023 | Rexulti |
| Biodelivery Sciences International, INC. | $13.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 | |
| Stimwave Technologies Incorporated | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Rosche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.